The size of the pharmacogenomics market was approximately $5,527.2 million in the year 2021, and it will advance at a 7.4% growth rate in the years to come and reach $10,505.3 million in 2030. According to the market research study published by P&S Intelligence. The growth of the industry is because of the growing occurrence of infectious sicknesses and numerous types of cancer, increasing acceptance of tailored medicine, a shift from reaction to deterrence worldwide, increasing rate of ADRs, and growing use of pharmacogenomics in the finding and expansion of medicines.
Within the application segment, oncology contributed about $2,682.2 million in revenue in the year 2021 in the pharmacogenomics market. This tendency will stay this way in the near future as well because of the quick acceptance of pharmacogenomics in the devel opment of drugs, particularly in progressive economies; the high occurrence of diverse kinds of cancers, and the increasing requirement for biologics and the drugs which are based on monoclonal antibodies for the treatment of tumors. Moreover, cancer pharmacogenomics has aided a number of key advancements in cancer treatment. For example, a chemotherapeutic drug Irinotecan is used for the treatment of colon cancer.
Request for sample pages of this report: https://www.psmarketresearch.com/market-analysis/pharmacogenomics-market/report-sample
ADRs are undesirable effects of a specific medication happening at the time of clinical use. Furthermore, they can be long-lasting, therefore harmfully affecting the life of a patient. In life-threatening cases, ADRs can cause illness and mortality. The growing volume of medicines in the pharmacogenomics market, rising elderly population, and thriving inclination toward polypharmacy are steadily pushing the occurrence of ADRs worldwide. As per the FDA, in the year 2020, in the U.S., 2.22 million ADRs were reported, 1.18 million out of which were serious and 0.19 million led to death.
The PCR technology had over 45% market share in the year 2021. This is chiefly because a small sample is used by PCR for analysis, for detecting microbial agents, and the procedure consumes about 4–8 hours, which is about 3 times faster than further procedures. Moreover, multiplex PCR is a kind of PCR that may amplify more than a few DNA sequences in one reaction. It is normally used to identify a diversity of antibiotic genes. Moreover, PCR has established higher positivity and sensitivity rates than strains and culture for both bacteria and fungi.
Inquiry before purchase of this report: https://www.psmarketresearch.com/send-enquiry?enquiry-url=pharmacogenomics-market
North America is the leader in the pharmacogenomics market, and the industry in the region will grow at a rate of 7% in the coming years. The surge in the adoption of pharmacogenomic practices in the region is driven by government initiatives for integrating targeted medicine approaches in the typical healthcare system. Furthermore, the U.S. FDA and the CLIA have been at the lead in the expansion of effective and apt policies and guidelines with the purpose of propelling the acceptance of pharmacogenomic tests by end-users.
There has been an increase in the requirement for pharmacogenomics due to the increasing prevalence of many infectious diseases.
Pharmacogenomics Market Size Breakdown by Segment
Polymerase Chain Reaction
By End User
Middle East and Africa
Browse Other Related Reports
Genomics Industry Size and Analysis Report by Solution, Technology, Application, End User – Global Market Growth Forecast to 2030
AI in Genomics Industry Size and Analysis Report by Delivery Mode, Functionality, Application, End User – Global Market Demand Forecast to 2030
Company Name: P&S Intelligence
Contact Person: Abhishek
Email: Send Email
Address:Noida Sector 2